The abstract is read at the publisher; the summary is JClub's.
Adding camrelizumab to neoadjuvant docetaxel plus carboplatin increased pathological complete response to 57.5% (134/233) versus 45.4% (54/119) in stage II–III triple-negative breast cancer.
- Why it matters: Anthracycline-containing neoadjuvant chemoimmunotherapy is linked to substantial toxicity, creating a need for effective anthracycline-free alternatives in stage II–III TNBC.
- What they did: In a multicenter, randomized, open-label phase III trial in China (14 hospitals; Dec 2022–Jun 2025), women aged 18–70 with untreated stage II–III TNBC received six cycles of docetaxel 75 mg/m² plus carboplatin (AUC=6) with or without camrelizumab 200 mg i.v. on day 3; pCR (ypT0/Tis ypN0) was assessed in the mITT population.
- The result: The camrelizumab combination improved pCR by an absolute 12.2% (95% CI 1.4–22.9; one-sided P=0.014) and showed grade 3–4 treatment-related adverse events of 24.9% versus 21.8%, with no treatment-related deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.